Skip to main content

Table 2 Univariate Analysis

From: Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis

Outcomes N Eval Prob (95% CI)
Neutrophil engraftment 236  
 1-year   97 (94–99)%
 2-year   97 (94–99)%
Platelet recovery 218  
 1-year   91 (87–94)%
 2-year   91 (87–95)%
Acute GVHD (II-IV) 239  
 180-day   36 (30–42)%
Acute GVHD (III-IV) 229  
 180-day   12 (8–17)%
Chronic GVHD 230  
 1-year   49 (43–56)%
 2-year   58 (51–64)%
Extensive cGVHD 230  
 1-year   39 (33–46)%
 2-year   46 (39–53)%
GRFS 230  
 1-year   35 (29–41)%
 2-year   27 (21–33)%
NRM 249  
 1-year   19 (14–24)%
 2-year   25 (20–31)%
 4-year   30 (24–36)%
Progression/relapse 249  
 1-year   15 (11–20)%
 2-year   19 (15–25)%
 4-year   21 (16–27)%
PFS 249  
 1-year   66 (60–72)%
 2-year   56 (49–62)%
 4-year   47 (41–54)%
Overall survival 249  
 1-year   73 (68–79)%
 2-year   63 (56–69)%
 4-year   56 (49–63)%
  1. GVHD graft-versus-host disease, Prob probability, CI confidence interval, N number, NRM non-relapse mortality, PFS progression-free survival, GRFS GVHD free, relapse-free survival
  2. Probabilities of acute GVHD, chronic GVHD, treatment-related mortality and progression/relapse were calculated using the cumulative incidence estimate. Progression-free survival and overall survival was calculated using the Kaplan-Meier product limit estimate
  3. Univariate analysis of alternative donor sources is shown in Additional file 1 Table S6